• info@reportsandmarkets.com
  • +44-020-3286-9338 (UK) +1-214-377-1121 (US)
  • Sign In
  • Register

OtherGlobal Oligonucleotide Therapeutics Market 2018 by Manufacturers, Countries, Type and Application, Forecast to 2023

  • RnM2414293
  • |
  • 14 September, 2018
  • |
  • Global
  • |
  • 120 pages
  • |
  • GIR (Global Info Research)
  • |
  • Other

Oligonucleotide therapeutics are different from conventional medicine as they can inhibit the expression of certain genes. This has given rise to innovative new oligonucleotides that can target specific genes and treat chronic diseases. The development of oligonucleotide therapeutics is done through chemically modified artificial nucleic acids. The artificial oligonucleotides are being developed which has improved in vivo stability and enhanced affinity to target mRNA.

Scope of the Report:

This report studies the Oligonucleotide Therapeutics market status and outlook of Global and major regions, from angles of players, countries, product types and end industries; this report analyzes the top players in global market, and splits the Oligonucleotide Therapeutics market by product type and applications/end industries.

Asia-Pacific is the fastest growing region as several oligonucleotide therapeutics manufacturers are looking forward to establishing manufacturing facilities in this region. Moreover, research undertaking and funding in the synthesis of oligonucleotides are expected to add on to the increasing demand.

The global Oligonucleotide Therapeutics market is valued at xx million USD in 2017 and is expected to reach xx million USD by the end of 2023, growing at a CAGR of xx% between 2017 and 2023.

The Asia-Pacific will occupy for more market share in following years, especially in China, also fast growing India and Southeast Asia regions.

North America, especially The United States, will still play an important role which cannot be ignored. Any changes from United States might affect the development trend of Oligonucleotide Therapeutics.

Europe also play important roles in global market, with market size of xx million USD in 2017 and will be xx million USD in 2023, with a CAGR of xx%.

Market Segment by Companies, this report covers

Pfizer

Merck

Biogen

PCI Biotech

SomaGenics

ContraVir

Alnylam

Regulus Therapeutics

Ionis Pharmaceuticals

Gilead

Santaris Pharma

Market Segment by Regions, regional analysis covers

North America (United States, Canada and Mexico)

Europe (Germany, France, UK, Russia and Italy)

Asia-Pacific (China, Japan, Korea, India and Southeast Asia)

South America (Brazil, Argentina, Colombia)

Middle East and Africa (Saudi Arabia, UAE, Egypt, Nigeria and South Africa)

Market Segment by Type, covers

Antisense

Ribozymes

Aptamers

miRNA

CpG/Immunostimulatory

RNAi

Others

Market Segment by Applications, can be divided into

Infectious Diseases

Oncology

Neurodegenerative Disorders

Cardiovascular Diseases

Kidney Diseases

Others


Table of Contents

1 Oligonucleotide Therapeutics Market Overview

1.1 Product Overview and Scope of Oligonucleotide Therapeutics

1.2 Classification of Oligonucleotide Therapeutics by Types

1.2.1 Global Oligonucleotide Therapeutics Revenue Comparison by Types (2017-2023)

1.2.2 Global Oligonucleotide Therapeutics Revenue Market Share by Types in 2017

1.2.3 Antisense

1.2.4 Ribozymes

1.2.5 Aptamers

1.2.6 miRNA

1.2.7 CpG/Immunostimulatory

1.2.8 RNAi

1.2.9 Others

1.3 Global Oligonucleotide Therapeutics Market by Application

1.3.1 Global Oligonucleotide Therapeutics Market Size and Market Share Comparison by Applications (2013-2023)

1.3.2 Infectious Diseases

1.3.3 Oncology

1.3.4 Neurodegenerative Disorders

1.3.5 Cardiovascular Diseases

1.3.6 Kidney Diseases

1.3.7 Others

1.4 Global Oligonucleotide Therapeutics Market by Regions

1.4.1 Global Oligonucleotide Therapeutics Market Size (Million USD) Comparison by Regions (2013-2023)

1.4.1 North America (USA, Canada and Mexico) Oligonucleotide Therapeutics Status and Prospect (2013-2023)

1.4.2 Europe (Germany, France, UK, Russia and Italy) Oligonucleotide Therapeutics Status and Prospect (2013-2023)

1.4.3 Asia-Pacific (China, Japan, Korea, India and Southeast Asia) Oligonucleotide Therapeutics Status and Prospect (2013-2023)

1.4.4 South America (Brazil, Argentina, Colombia) Oligonucleotide Therapeutics Status and Prospect (2013-2023)

1.4.5 Middle East and Africa (Saudi Arabia, UAE, Egypt, Nigeria and South Africa) Oligonucleotide Therapeutics Status and Prospect (2013-2023)

1.5 Global Market Size of Oligonucleotide Therapeutics (2013-2023)

2 Manufacturers Profiles

2.1 Pfizer

2.1.1 Business Overview

2.1.2 Oligonucleotide Therapeutics Type and Applications

2.1.2.1 Product A

2.1.2.2 Product B

2.1.3 Pfizer Oligonucleotide Therapeutics Revenue, Gross Margin and Market Share (2016-2017)

2.2 Merck

2.2.1 Business Overview

2.2.2 Oligonucleotide Therapeutics Type and Applications

2.2.2.1 Product A

2.2.2.2 Product B

2.2.3 Merck Oligonucleotide Therapeutics Revenue, Gross Margin and Market Share (2016-2017)

2.3 Biogen

2.3.1 Business Overview

2.3.2 Oligonucleotide Therapeutics Type and Applications

2.3.2.1 Product A

2.3.2.2 Product B

2.3.3 Biogen Oligonucleotide Therapeutics Revenue, Gross Margin and Market Share (2016-2017)

2.4 PCI Biotech

2.4.1 Business Overview

2.4.2 Oligonucleotide Therapeutics Type and Applications

2.4.2.1 Product A

2.4.2.2 Product B

2.4.3 PCI Biotech Oligonucleotide Therapeutics Revenue, Gross Margin and Market Share (2016-2017)

2.5 SomaGenics

2.5.1 Business Overview

2.5.2 Oligonucleotide Therapeutics Type and Applications

2.5.2.1 Product A

2.5.2.2 Product B

2.5.3 SomaGenics Oligonucleotide Therapeutics Revenue, Gross Margin and Market Share (2016-2017)

2.6 ContraVir

2.6.1 Business Overview

2.6.2 Oligonucleotide Therapeutics Type and Applications

2.6.2.1 Product A

2.6.2.2 Product B

2.6.3 ContraVir Oligonucleotide Therapeutics Revenue, Gross Margin and Market Share (2016-2017)

2.7 Alnylam

2.7.1 Business Overview

2.7.2 Oligonucleotide Therapeutics Type and Applications

2.7.2.1 Product A

2.7.2.2 Product B

2.7.3 Alnylam Oligonucleotide Therapeutics Revenue, Gross Margin and Market Share (2016-2017)

2.8 Regulus Therapeutics

2.8.1 Business Overview

2.8.2 Oligonucleotide Therapeutics Type and Applications

2.8.2.1 Product A

2.8.2.2 Product B

2.8.3 Regulus Therapeutics Oligonucleotide Therapeutics Revenue, Gross Margin and Market Share (2016-2017)

2.9 Ionis Pharmaceuticals

2.9.1 Business Overview

2.9.2 Oligonucleotide Therapeutics Type and Applications

2.9.2.1 Product A

2.9.2.2 Product B

2.9.3 Ionis Pharmaceuticals Oligonucleotide Therapeutics Revenue, Gross Margin and Market Share (2016-2017)

2.10 Gilead

2.10.1 Business Overview

2.10.2 Oligonucleotide Therapeutics Type and Applications

2.10.2.1 Product A

2.10.2.2 Product B

2.10.3 Gilead Oligonucleotide Therapeutics Revenue, Gross Margin and Market Share (2016-2017)

2.11 Santaris Pharma

2.11.1 Business Overview

2.11.2 Oligonucleotide Therapeutics Type and Applications

2.11.2.1 Product A

2.11.2.2 Product B

2.11.3 Santaris Pharma Oligonucleotide Therapeutics Revenue, Gross Margin and Market Share (2016-2017)

3 Global Oligonucleotide Therapeutics Market Competition, by Players

3.1 Global Oligonucleotide Therapeutics Revenue and Share by Players (2013-2018)

3.2 Market Concentration Rate

3.2.1 Top 5 Oligonucleotide Therapeutics Players Market Share

3.2.2 Top 10 Oligonucleotide Therapeutics Players Market Share

3.3 Market Competition Trend

4 Global Oligonucleotide Therapeutics Market Size by Regions

4.1 Global Oligonucleotide Therapeutics Revenue and Market Share by Regions

4.2 North America Oligonucleotide Therapeutics Revenue and Growth Rate (2013-2018)

4.3 Europe Oligonucleotide Therapeutics Revenue and Growth Rate (2013-2018)

4.4 Asia-Pacific Oligonucleotide Therapeutics Revenue and Growth Rate (2013-2018)

4.5 South America Oligonucleotide Therapeutics Revenue and Growth Rate (2013-2018)

4.6 Middle East and Africa Oligonucleotide Therapeutics Revenue and Growth Rate (2013-2018)

5 North America Oligonucleotide Therapeutics Revenue by Countries

5.1 North America Oligonucleotide Therapeutics Revenue by Countries (2013-2018)

5.2 USA Oligonucleotide Therapeutics Revenue and Growth Rate (2013-2018)

5.3 Canada Oligonucleotide Therapeutics Revenue and Growth Rate (2013-2018)

5.4 Mexico Oligonucleotide Therapeutics Revenue and Growth Rate (2013-2018)

6 Europe Oligonucleotide Therapeutics Revenue by Countries

6.1 Europe Oligonucleotide Therapeutics Revenue by Countries (2013-2018)

6.2 Germany Oligonucleotide Therapeutics Revenue and Growth Rate (2013-2018)

6.3 UK Oligonucleotide Therapeutics Revenue and Growth Rate (2013-2018)

6.4 France Oligonucleotide Therapeutics Revenue and Growth Rate (2013-2018)

6.5 Russia Oligonucleotide Therapeutics Revenue and Growth Rate (2013-2018)

6.6 Italy Oligonucleotide Therapeutics Revenue and Growth Rate (2013-2018)

7 Asia-Pacific Oligonucleotide Therapeutics Revenue by Countries

7.1 Asia-Pacific Oligonucleotide Therapeutics Revenue by Countries (2013-2018)

7.2 China Oligonucleotide Therapeutics Revenue and Growth Rate (2013-2018)

7.3 Japan Oligonucleotide Therapeutics Revenue and Growth Rate (2013-2018)

7.4 Korea Oligonucleotide Therapeutics Revenue and Growth Rate (2013-2018)

7.5 India Oligonucleotide Therapeutics Revenue and Growth Rate (2013-2018)

7.6 Southeast Asia Oligonucleotide Therapeutics Revenue and Growth Rate (2013-2018)

8 South America Oligonucleotide Therapeutics Revenue by Countries

8.1 South America Oligonucleotide Therapeutics Revenue by Countries (2013-2018)

8.2 Brazil Oligonucleotide Therapeutics Revenue and Growth Rate (2013-2018)

8.3 Argentina Oligonucleotide Therapeutics Revenue and Growth Rate (2013-2018)

8.4 Colombia Oligonucleotide Therapeutics Revenue and Growth Rate (2013-2018)

9 Middle East and Africa Revenue Oligonucleotide Therapeutics by Countries

9.1 Middle East and Africa Oligonucleotide Therapeutics Revenue by Countries (2013-2018)

9.2 Saudi Arabia Oligonucleotide Therapeutics Revenue and Growth Rate (2013-2018)

9.3 UAE Oligonucleotide Therapeutics Revenue and Growth Rate (2013-2018)

9.4 Egypt Oligonucleotide Therapeutics Revenue and Growth Rate (2013-2018)

9.5 Nigeria Oligonucleotide Therapeutics Revenue and Growth Rate (2013-2018)

9.6 South Africa Oligonucleotide Therapeutics Revenue and Growth Rate (2013-2018)

10 Global Oligonucleotide Therapeutics Market Segment by Type

10.1 Global Oligonucleotide Therapeutics Revenue and Market Share by Type (2013-2018)

10.2 Global Oligonucleotide Therapeutics Market Forecast by Type (2018-2023)

10.3 Antisense Revenue Growth Rate (2013-2023)

10.4 Ribozymes Revenue Growth Rate (2013-2023)

10.5 Aptamers Revenue Growth Rate (2013-2023)

10.6 miRNA Revenue Growth Rate (2013-2023)

10.7 CpG/Immunostimulatory Revenue Growth Rate (2013-2023)

10.8 RNAi Revenue Growth Rate (2013-2023)

10.9 Others Revenue Growth Rate (2013-2023)

11 Global Oligonucleotide Therapeutics Market Segment by Application

11.1 Global Oligonucleotide Therapeutics Revenue Market Share by Application (2013-2018)

11.2 Oligonucleotide Therapeutics Market Forecast by Application (2018-2023)

11.3 Infectious Diseases Revenue Growth (2013-2018)

11.4 Oncology Revenue Growth (2013-2018)

11.5 Neurodegenerative Disorders Revenue Growth (2013-2018)

11.6 Cardiovascular Diseases Revenue Growth (2013-2018)

11.7 Kidney Diseases Revenue Growth (2013-2018)

11.8 Others Revenue Growth (2013-2018)

12 Global Oligonucleotide Therapeutics Market Size Forecast (2018-2023)

12.1 Global Oligonucleotide Therapeutics Market Size Forecast (2018-2023)

12.2 Global Oligonucleotide Therapeutics Market Forecast by Regions (2018-2023)

12.3 North America Oligonucleotide Therapeutics Revenue Market Forecast (2018-2023)

12.4 Europe Oligonucleotide Therapeutics Revenue Market Forecast (2018-2023)

12.5 Asia-Pacific Oligonucleotide Therapeutics Revenue Market Forecast (2018-2023)

12.6 South America Oligonucleotide Therapeutics Revenue Market Forecast (2018-2023)

12.7 Middle East and Africa Oligonucleotide Therapeutics Revenue Market Forecast (2018-2023)

13 Research Findings and Conclusion

14 Appendix

14.1 Methodology

14.2 Data Source


captcha
Enter the code in the box:


captcha
Enter the code in the box:

Single User License (PDF)

  • This license allows for use of a publication by one person.
  • This person may not print out a single copy of the publication.
  • This person can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.
  • This person cannot share the publication (or any information contained therein) with any other person or persons.
  • Unless a Enterprise License is purchased, a Single User License must be purchased for every person that wishes to use the publication within the same organization.
  • Customers who infringe these license terms are liable for a Global license fee.

 

Site License (PDF)*

  • This license allows for use of a publication by all users within one corporate location, e.g. a regional office.
  • These users may print out a single copy of the publication.
  • These users can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.
  • These users cannot share the publication (or any information contained therein) with any other person or persons outside the corporate location for which the publication is purchased.
  • Unless a Enterprise License is purchased, a Site User License must be purchased for every corporate location by an organization that wishes to use the publication within the same organization.
  • Customers who infringe these license terms are liable for a Global license fee.

 

Global License (PDF)*

  • This license allows for use of a publication by unlimited users within the purchasing organization e.g. all employees of a single company.
  • Each of these people may use the publication on any computer, and may print out the report, but may not share the publication (or any information contained therein) with any other person or persons outside of the organization.
  • These employees of purchasing organization can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.

*If Applicable.


captcha
Enter the code in the box:



Summary:
Get latest Market Research Reports on Oligonucleotide Therapeutics . Industry analysis & Market Report on Oligonucleotide Therapeutics is a syndicated market report, published as Global Oligonucleotide Therapeutics Market 2018 by Manufacturers, Countries, Type and Application, Forecast to 2023. It is complete Research Study and Industry Analysis of Oligonucleotide Therapeutics market, to understand, Market Demand, Growth, trends analysis and Factor Influencing market.


REPORT YOU MIGHT BE INTERESTED

Purchase this Report

$3,480.00
$5,220.00
$6,960.00
2,336.82
3,505.23
4,673.64
3,202.30
4,803.44
6,404.59
421,567.20
632,350.80
843,134.40
230,770.63
346,155.95
461,541.26
Add To Cart Credit card Logo

Related Reports


Reason to Buy